A. de C.V. (“VENA”) has launched an offer to purchase for cash (the “Tender Offer”) any and all of its outstanding 10.75% senior secured guaranteed notes due 2011 (the “Notes”).
The aggregate principal amount outstanding of the Notes as of this date is $250 million. Concurrently with the Tender Offer, VENA is soliciting consents (the “Consent Solicitation”) from the holders of the Notes to proposed amendments to the indenture under which the Notes were originally issued which, among other things, will enable the release of certain liens on the collateral for the Notes.
The Tender Offer will remain open for 20 business days and will expire on February 7, 2007 at 12:00 midnight EST, unless extended by VENA. Holders of the Notes must tender their notes prior to 5:00 p.m. EST on January 24, 2007 to receive the consent payment unless such date is extended by VENA.
Pursuant to the Tender Offer and Consent Solicitation, holders of the Notes will receive certain cash consideration plus accrued interest for each $1,000 principal amount of the Notes tendered and accepted for payment as more fully set forth in the Offer to Purchase and Consent Solicitation Statement made available to holders of the Notes. The consideration will be based on a fixed spread of 50 bps over the bid-side yield of the reference U.S. Treasury security indicated in the Offer to Purchase and Consent Solicitation Statement.
The Tender Offer and Consent Solicitation are subject to Vitro obtaining financing in order to, among other things, transfer sufficient funds to VENA to pay for the Tender Offer and Consent Solicitation and to effect a covenant defeasance of any non-tendered Notes, reaching a minimum tender aggregate amount of Notes as well as other certain conditions as more fully set forth in the Offer to Purchase and Consent Solicitation Statement.
The Tender Offer and Consent Solicitation are part of a thorough major initiative being implemented by Vitro to improve its capital structure, debt maturity profile and liquidity position. Through this initiative and others implemented last year, Vitro seeks to reduce its leverage and cost of capital to improve its operations and credit profile.